11. Myasthenia
226 clinical trials,   172 drugs   (DrugBank: 45 drugs),   43 drug target genes,   118 drug target pathways

Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03510546
(ClinicalTrials.gov)
April 9, 20186/4/2018Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia GravisEffect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia GravisMyasthenia GravisDrug: Pyridostigmine;Drug: Placebo oral capsuleUniversity of AarhusAarhus University HospitalRecruiting18 Years90 YearsAll44Phase 4Denmark
2EUCTR2017-002599-15-DK
(EUCTR)
07/11/201707/07/2017Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis.Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis. Myasthenia Gravis
MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Myasthenia gravis and related conditions;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: Mestinon
INN or Proposed INN: pyridostigmine
Other descriptive name: PYRIDOSTIGMINE
Aarhus UniversityNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 4Denmark